Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer

NCT04900311 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

490

Enrollment

OTHER

Sponsor class

Conditions

HER2+ Early or Locally Advanced Breast Cancer

Interventions

DRUG: pyrotinib + trastuzumab + nab-paclitaxel
DRUG: pertuzumab + trastuzumab + nab-paclitaxel

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators

[object Object]